Panduratin A mitigates inflammation and oxidative stress in DSS-induced colitis mice model

  • Future Sci OA. 2024 Dec;10(1):2428129. doi: 10.1080/20565623.2024.2428129.
Abdelrahim Alqudah  1 ,  Esam Qnais  2 ,  Omar Gammoh  3 ,  Yousra Bseiso  2 ,  Mohammed Wedyan  2 ,  Muna Oqal  4
Affiliations
  • 1. Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan.
  • 2. Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
  • 3. Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.
  • 4. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan.
PMID: 39559852 DOI: 10.1080/20565623.2024.2428129
Abstract

Aim: This study explored Panduratin A's protective effects against DSS-induced colitis in mice, focusing on reducing inflammation and oxidative stress in the colon.

Methods: Mice were treated with dextran sodium sulfate (DSS) and Panduratin A (3, 6, 18 mg/kg), and changes in body weight, colon length, Disease Activity Index (DAI), histopathology, inflammation markers including tumor necrosis factor- α (TNF-α), Interleukin-1 β (IL-1β), Myeloperoxidase (MPO), and oxidative stress, Malondialdehyde (MDA) were evaluated.

Results: Panduratin A significantly reversed DSS-induced symptoms, including body weight loss, colonic length shortening, and DAI increase, while reducing histopathological damage. It lowered inflammatory markers and oxidative stress, suppressed NF-κB activation, and enhanced Nrf2 and HO-1 expression.

Conclusion: Panduratin A shows promise as a colitis treatment, warranting further research for broader clinical application.

Keywords
DSS-induced colitis; Panduratin A; anti-inflammatory; oxidative stress; ulcerative colitis.
Products